1. Beta-lactam antibiotics achieve bactericidal activity through which of the following mechanisms?
A) Competitive inhibition of the D-alanine racemase enzyme that converts L-alanine to D-alanine, depleting the substrate pool for peptidoglycan synthesis
B) Covalent acylation of the active-site serine residue of penicillin-binding protein transpeptidases, forming a stable acyl-enzyme intermediate that permanently inactivates cross-linking
C) Chelation of divalent cations required for outer membrane lipopolysaccharide stability, leading to membrane disruption and cell lysis
D) Competitive inhibition of the MurA enzyme that catalyzes the first committed step in peptidoglycan precursor synthesis
E) Intercalation into the lipid bilayer of the bacterial cytoplasmic membrane, dissipating the proton motive force required for ATP synthesis
ANSWER: B
Rationale:
Beta-lactam antibiotics are structural analogs of the D-alanyl-D-alanine terminus of the peptidoglycan stem peptide, which is the natural substrate of transpeptidase enzymes (penicillin-binding proteins, or PBPs). The beta-lactam carbonyl carbon forms a covalent acyl-enzyme intermediate with the active-site serine residue of the PBP transpeptidase. This acylation is effectively irreversible under physiological conditions because the intermediate hydrolyzes extremely slowly. With transpeptidation blocked, peptidoglycan cross-linking ceases while autolysins continue degrading the cell wall, producing structural weakness, osmotic stress, and bactericidal lysis.
Option A: Option A is incorrect: D-alanine racemase is the target of cycloserine, not beta-lactams; beta-lactams act downstream at the transpeptidation step, not at amino acid precursor synthesis.
Option C: Option C is incorrect: divalent cation chelation and outer membrane disruption describe the mechanism of polymyxins, not beta-lactams.
Option D: Option D is incorrect: MurA inhibition describes the mechanism of fosfomycin, which blocks the first committed step of peptidoglycan precursor synthesis intracellularly; beta-lactams act extracellularly at the transpeptidase.
Option E: Option E is incorrect: membrane depolarization via proton motive force disruption describes the mechanism of daptomycin, a lipopeptide antibiotic with a completely different structure and target.
2. The pharmacodynamic parameter that best predicts the bactericidal efficacy of penicillins and other beta-lactam antibiotics is:
A) The peak free drug concentration divided by the minimum inhibitory concentration (Cmax/MIC), indicating that a high transient peak is required for killing
B) The area under the free drug concentration-time curve over 24 hours divided by the MIC (fAUC/MIC), reflecting total drug exposure as the primary driver of efficacy
C) The trough free drug concentration expressed as a multiple of the MIC, because residual drug at the dosing nadir determines whether regrowth occurs
D) The percentage of the dosing interval during which the free drug concentration exceeds the minimum inhibitory concentration (fT>MIC), typically requiring 40–50% of the interval for bactericidal effect
E) The ratio of total (protein-bound plus free) drug AUC to MIC, because protein-bound drug acts as a reservoir that contributes directly to bacterial killing
ANSWER: D
Rationale:
Beta-lactam antibiotics exhibit time-dependent (concentration-independent) killing. Once free drug concentrations exceed the MIC by approximately four- to fivefold, further concentration increases produce no additional bactericidal effect; what determines outcome is how long concentrations remain above the MIC threshold. The pharmacodynamic target for bactericidal activity with most beta-lactams is fT>MIC of approximately 40–50% of the dosing interval; for bacteriostasis a lower threshold suffices, but clinical cure in serious infections generally requires the bactericidal target. This principle directly informs extended and continuous infusion strategies for piperacillin-tazobactam and meropenem against organisms with elevated MICs.
Option A: Option A is incorrect: Cmax/MIC drives efficacy for concentration-dependent antibiotics such as aminoglycosides and fluoroquinolones, not for beta-lactams; peak concentration above four to five times the MIC adds no benefit for penicillins.
Option B: Option B is incorrect: fAUC/MIC is the primary pharmacodynamic driver for fluoroquinolones and vancomycin, not beta-lactams; while total exposure matters broadly, it is not the mechanistic index for this drug class.
Option C: Option C is incorrect: trough-based targets are used clinically for vancomycin and aminoglycoside monitoring but do not define the pharmacodynamic mechanism for beta-lactam killing.
Option E: Option E is incorrect: only free (unbound) drug is pharmacologically active; protein-bound drug does not contribute to bacterial killing and is not included in the predictive pharmacodynamic parameter.
3. A 68-year-old man with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia and an estimated glomerular filtration rate (eGFR) of 18 mL/min/1.73 m² requires definitive antistaphylococcal therapy. Which penicillin requires no dose adjustment in this setting, and why?
A) Nafcillin, because it is predominantly eliminated by hepatic biliary excretion (approximately 70–80%), making its clearance independent of renal function
B) Oxacillin, because its renal clearance is offset by active tubular secretion that remains intact even in severe renal impairment
C) Ampicillin-sulbactam, because sulbactam inhibits the tubular secretion of ampicillin, normalizing its pharmacokinetics in renal failure
D) Dicloxacillin, because it is taken orally and gastrointestinal absorption is not affected by renal function
E) Piperacillin-tazobactam, because tazobactam undergoes non-renal metabolism that compensates for reduced piperacillin clearance in renal failure
ANSWER: A
Rationale:
Among the antistaphylococcal penicillins, nafcillin is the only agent that does not require dose adjustment in renal impairment because approximately 70–80% of a nafcillin dose is eliminated by hepatic biliary excretion rather than renal mechanisms. This pharmacokinetic property makes nafcillin the preferred antistaphylococcal penicillin for MSSA infections in patients with significant renal impairment, including those with eGFR below 30 mL/min or on dialysis. For serious MSSA infections such as bacteremia or endocarditis, an antistaphylococcal penicillin (nafcillin or oxacillin) outperforms vancomycin in clinical outcomes and should be used when possible; nafcillin's hepatic elimination makes it the rational choice when renal function is severely compromised.
Option B: Option B is incorrect: oxacillin undergoes both renal and hepatic elimination; while dose adjustment in mild-to-moderate renal impairment is not always required, significant renal failure does affect its clearance, and it is not preferred over nafcillin in this setting.
Option C: Option C is incorrect: sulbactam does not inhibit tubular secretion of ampicillin in a compensatory way; both components of ampicillin-sulbactam are renally eliminated and both require dose adjustment in renal failure; additionally, ampicillin-sulbactam is not an antistaphylococcal agent of first choice for MSSA bacteremia.
Option D: Option D is incorrect: while gastrointestinal absorption of dicloxacillin is not affected by renal function, dicloxacillin itself undergoes significant renal elimination and accumulates in severe renal failure; furthermore, oral dicloxacillin is not appropriate for bacteremia.
Option E: Option E is incorrect: piperacillin-tazobactam is predominantly renally eliminated (greater than 68% of piperacillin and tazobactam as unchanged drug or metabolites), requires dose reduction at eGFR below 40 mL/min, and is not indicated for MSSA bacteremia in preference to antistaphylococcal penicillins.
4. The MERINO trial enrolled patients with bloodstream infections due to ceftriaxone-resistant Escherichia coli or Klebsiella pneumoniae and randomized them to piperacillin-tazobactam versus meropenem. What was the primary finding, and what is its clinical implication?
A) Thirty-day mortality was equivalent between arms, validating piperacillin-tazobactam as an acceptable carbapenem-sparing alternative for ESBL bacteremia when in vitro susceptibility is confirmed
B) Clinical cure rates were similar but piperacillin-tazobactam was associated with higher rates of Clostridioides difficile infection, recommending meropenem as preferred based on safety rather than efficacy
C) Thirty-day mortality was significantly higher in the piperacillin-tazobactam arm (12.3% vs. 3.7%), establishing that pip-tazo should not be used as definitive therapy for ESBL-producing gram-negative bacteremia even when in vitro susceptibility is reported
D) The trial was stopped early for benefit in the meropenem arm due to dramatically superior microbiological eradication rates, but clinical outcome differences were not statistically significant
E) Piperacillin-tazobactam achieved equivalent outcomes only when administered by extended 4-hour infusion, suggesting that pharmacodynamic optimization can bridge the clinical gap between agents
ANSWER: C
Rationale:
The MERINO trial (Harris et al., JAMA 2018) randomized patients with ceftriaxone-resistant Enterobacterales bacteremia — a phenotypic marker for extended-spectrum beta-lactamase (ESBL) or AmpC production — to piperacillin-tazobactam 4.5 g every 6 hours versus meropenem 1 g every 8 hours. The primary outcome, 30-day mortality, was 12.3% in the piperacillin-tazobactam arm versus 3.7% in the meropenem arm, a statistically significant and clinically large difference (absolute risk difference approximately 8.6 percentage points). The likely mechanism for this inferior performance is the inoculum effect: in bacteremia, the high bacterial burden overwhelms the beta-lactamase inhibitor tazobactam's capacity to protect piperacillin, allowing ESBL enzymes to inactivate the drug despite in vitro susceptibility testing reporting the isolate as susceptible. This trial definitively established that in vitro susceptibility to pip-tazo does not predict clinical efficacy for ESBL bacteremia, and that carbapenems should be used for definitive treatment.
Option A: Option A is incorrect: the trial demonstrated a significant mortality difference, not equivalence; piperacillin-tazobactam was not validated as a carbapenem-sparing strategy for this indication.
Option B: Option B is incorrect: Clostridioides difficile rates were not the basis for the trial's conclusions; the finding was a mortality difference, not a safety signal favoring meropenem.
Option D: Option D is incorrect: the trial was not stopped early; it completed enrollment, and both microbiological and clinical outcomes favored meropenem.
Option E: Option E is incorrect: extended infusion of piperacillin-tazobactam was not tested in this trial, and no post-hoc analysis has established that infusion optimization eliminates the outcome difference seen in ESBL bacteremia.
5. Which of the following correctly describes the molecular mechanism by which methicillin-resistant Staphylococcus aureus (MRSA) resists the activity of all beta-lactam antibiotics?
A) MRSA produces a plasmid-encoded class A beta-lactamase (penicillinase) with expanded hydrolytic activity against all penicillinase-stable penicillins, including oxacillin and nafcillin
B) MRSA overexpresses wild-type PBP2 and PBP3, which together maintain cell wall cross-linking even when PBP1 and PBP4 are inhibited by beta-lactam concentrations achievable in clinical practice
C) MRSA acquires mutations in the promoter region of its native PBP2 gene, increasing constitutive expression of PBP2 to levels that saturate available beta-lactam molecules
D) MRSA downregulates porin expression in its cell wall, preventing beta-lactam antibiotics from reaching the penicillin-binding proteins on the cytoplasmic membrane surface
E) MRSA expresses PBP2a, encoded by the mecA gene carried on the staphylococcal cassette chromosome mec (SCCmec), which has extremely low affinity for all beta-lactam antibiotics and retains transpeptidase activity at clinically achievable drug concentrations
ANSWER: E
Rationale:
MRSA resistance to beta-lactams is mediated by the mecA gene (or its less common homolog mecC), which encodes PBP2a — a modified transpeptidase with structural changes in the active site that drastically reduce its affinity for all beta-lactam antibiotics. Unlike native PBPs that are effectively and permanently acylated by beta-lactams at clinical drug concentrations, PBP2a continues to catalyze peptidoglycan transpeptidation even in the presence of very high beta-lactam concentrations, allowing the organism to maintain cell wall integrity and proliferate despite drug exposure. The mecA gene is carried on a mobile genetic element called the staphylococcal cassette chromosome mec (SCCmec), which has disseminated broadly among staphylococcal populations in both healthcare and community settings. No standard beta-lactam antibiotic is clinically effective against MRSA, with the limited exception of ceftaroline (a fifth-generation cephalosporin with affinity for PBP2a).
Option A: Option A is incorrect: standard staphylococcal penicillinases (class A beta-lactamases) are inhibited by the bulky side chains of antistaphylococcal penicillins; MRSA resistance is not mediated by an expanded penicillinase but by an altered PBP target.
Option B: Option B is incorrect: overexpression of wild-type PBPs does not confer beta-lactam resistance because wild-type PBPs retain high affinity for beta-lactams and are inactivated normally; resistance requires an altered, low-affinity PBP.
Option C: Option C is incorrect: promoter upregulation of wild-type PBP2 would not confer resistance for the same reason; the target must have reduced affinity, not simply be present in greater quantity.
Option D: Option D is incorrect: Staphylococcus aureus is a gram-positive organism and lacks an outer membrane with porin channels; porin-mediated permeability reduction is a resistance mechanism of gram-negative bacteria, not staphylococci.
6. Compared to natural penicillins (penicillin G and V), aminopenicillins such as ampicillin and amoxicillin have expanded gram-negative coverage. Which structural modification is responsible, and what organisms does it add to the spectrum?
A) Addition of a methoxy group to the beta-lactam ring stabilizes the molecule against gram-negative periplasmic beta-lactamases, enabling activity against all Enterobacteriaceae including Klebsiella pneumoniae and Pseudomonas aeruginosa
B) Introduction of an amino group at the alpha carbon of the acyl side chain increases hydrophilicity and outer membrane porin traversal, extending coverage to include non-beta-lactamase-producing Haemophilus influenzae, susceptible Escherichia coli, Proteus mirabilis, and Enterococcus faecalis
C) Replacement of the thiazolidine ring with an oxazolidine ring reduces molecular size, allowing passage through the narrow OprD porin found specifically in gram-negative enteric organisms
D) Addition of a piperazine side chain at the 6-position of the penicillin nucleus extends coverage to Pseudomonas aeruginosa and all gram-negative anaerobes while retaining full gram-positive activity
E) Esterification of the carboxyl group at position 3 of the beta-lactam nucleus increases lipophilicity, improving penetration through the gram-negative outer membrane into the periplasmic space
ANSWER: B
Rationale:
The aminopenicillins (ampicillin, amoxicillin) differ from natural penicillins by the addition of an amino group at the alpha carbon of the acyl side chain attached to the 6-aminopenicillanic acid nucleus. This structural change increases the overall hydrophilicity of the molecule, facilitating traversal through the water-filled porin channels (principally OmpF and OmpC) in the outer membrane of gram-negative bacteria. The result is clinically meaningful expansion of coverage to include Haemophilus influenzae (non-beta-lactamase-producing strains), susceptible community-acquired Escherichia coli, Proteus mirabilis, Salmonella species, and Enterococcus faecalis, while fully retaining gram-positive activity against streptococci and penicillin-susceptible organisms. Critically, this modification does not confer beta-lactamase stability; both ampicillin and amoxicillin remain susceptible to hydrolysis by class A beta-lactamases, which are ubiquitous in Klebsiella pneumoniae and common in E. coli.
Option A: Option A is incorrect: a methoxy group on the beta-lactam ring describes the structural basis of methicillin and the antistaphylococcal penicillins — these agents are more beta-lactamase-stable but have reduced gram-negative activity, not expanded; Klebsiella and Pseudomonas are not covered by aminopenicillins.
Option C: Option C is incorrect: aminopenicillins retain the thiazolidine ring of the penicillin nucleus; no ring replacement occurs, and OprD is a carbapenem-specific porin in Pseudomonas, not a general enteric porin.
Option D: Option D is incorrect: a piperazine side chain at the 6-position describes the structural feature of piperacillin, a ureidopenicillin, not an aminopenicillin; piperacillin's antipseudomonal activity is a distinct structural achievement.
Option E: Option E is incorrect: esterification of position 3 is not a feature of aminopenicillins; lipophilicity enhancement would reduce, not improve, traversal of the water-filled porin channels that beta-lactams use to enter gram-negative periplasm.
7. A blood culture grows Klebsiella pneumoniae harboring an NDM (New Delhi metallo-beta-lactamase) enzyme. Which of the following correctly characterizes the implications for antibiotic selection?
A) NDM is an Ambler class B metallo-beta-lactamase that requires zinc as a cofactor, hydrolyzes virtually all beta-lactams including carbapenems but spares aztreonam, and is not inhibited by serine-based beta-lactamase inhibitors such as clavulanate, tazobactam, or avibactam
B) NDM is an Ambler class A serine beta-lactamase that is effectively inhibited by avibactam, making ceftazidime-avibactam the treatment of choice for NDM-producing organisms
C) NDM is an Ambler class C AmpC cephalosporinase that is chromosomally encoded and inducible, requiring extended-infusion carbapenems to achieve reliable pharmacodynamic target attainment
D) NDM is an Ambler class D OXA-type enzyme that preferentially hydrolyzes oxacillin and carbapenems, and is effectively inhibited by sulbactam when administered in combination with ampicillin
E) NDM hydrolyzes all beta-lactam antibiotics including aztreonam and is partially inhibited by clavulanate, making amoxicillin-clavulanate with dose escalation a potential carbapenem-sparing strategy
ANSWER: A
Rationale:
NDM (New Delhi metallo-beta-lactamase) belongs to Ambler class B, the metallo-beta-lactamases, which use zinc ions at their active site as a cofactor for beta-lactam ring hydrolysis rather than the active-site serine residue used by class A, C, and D enzymes. This mechanistic distinction has critical therapeutic implications: class B enzymes are not inhibited by any clinically available serine-based beta-lactamase inhibitor (clavulanate, sulbactam, tazobactam, avibactam, vaborbactam, or relebactam), because these inhibitors work by acylating the serine residue that class B enzymes do not possess. NDM and other metallo-beta-lactamases (VIM, IMP) hydrolyze virtually all beta-lactam antibiotics including carbapenems, but importantly do not hydrolyze aztreonam (a monobactam), because aztreonam's unique chemical structure resists metallo-beta-lactamase hydrolysis. However, NDM-producing organisms frequently co-harbor serine-based ESBLs that do hydrolyze aztreonam, limiting its clinical utility unless susceptibility is confirmed. Ceftazidime-avibactam plus aztreonam is an emerging combination strategy.
Option B: Option B is incorrect: avibactam inhibits class A, C, and some class D serine beta-lactamases but has no activity against class B metallo-beta-lactamases; ceftazidime-avibactam alone cannot treat NDM-producing organisms.
Option C: Option C is incorrect: NDM is not an AmpC cephalosporinase (class C); AmpC enzymes are serine beta-lactamases encoded chromosomally in many Enterobacteriaceae and are distinct from metallo-beta-lactamases both mechanistically and in spectrum of hydrolysis.
Option D: Option D is incorrect: NDM is not an OXA-type (class D) enzyme; OXA-type carbapenemases include OXA-23 (Acinetobacter) and OXA-48 (Klebsiella); sulbactam has limited activity against OXA carbapenemases and is not a standard treatment strategy for them.
Option E: Option E is incorrect: NDM does not hydrolyze aztreonam (the monobactam is spared by class B enzymes), and clavulanate does not inhibit class B metallo-beta-lactamases; amoxicillin-clavulanate would be completely ineffective against an NDM-producing carbapenem-resistant organism.
8. Under normal physiological conditions, the cerebrospinal fluid (CSF)-to-plasma ratio for penicillins is approximately 1–2%. In the setting of bacterial meningitis, this ratio rises substantially. What is the primary mechanism responsible for improved CNS (central nervous system) penetration during meningeal inflammation?
A) Meningeal inflammation increases cerebral blood flow and cardiac output, raising the total delivered drug load to the choroid plexus and passively increasing CSF drug concentrations
B) Inflammatory cytokines upregulate the organic anion transporter OAT1 in the proximal tubule, reducing renal penicillin clearance and raising plasma concentrations that drive passive diffusion into CSF
C) Bacterial lipopolysaccharide (LPS) in the CSF directly inhibits the P-glycoprotein efflux transporter on the luminal surface of brain endothelial cells, trapping penicillin within the CNS compartment once it enters
D) Meningeal inflammation disrupts the tight junctions of the blood-brain barrier and downregulates efflux transporters including P-glycoprotein and organic anion transporters, increasing passive penicillin permeability and reducing active efflux from CSF
E) Fever associated with meningitis increases the lipophilicity of penicillin at body temperature, allowing the drug to partition into membrane lipids and cross the blood-brain barrier by transcellular diffusion
ANSWER: D
Rationale:
Under normal conditions, penicillin CSF penetration is very low (CSF-to-plasma ratio approximately 1–2%) because the blood-brain barrier actively excludes these hydrophilic, negatively charged molecules through two mechanisms: the tight junctions between brain endothelial cells prevent paracellular diffusion, and active efflux transporters including P-glycoprotein on the luminal (blood-facing) surface and organic anion transporters on the abluminal surface actively pump penicillin back into the bloodstream after any transcellular entry. During bacterial meningitis, intense inflammatory mediators — cytokines, prostaglandins, and complement activation products — disrupt the tight junctions and downregulate these efflux transporters, increasing passive permeability and reducing active drug removal. CSF penetration rises to approximately 5–10% of plasma concentrations during active meningeal inflammation, which is sufficient to achieve therapeutic concentrations when high-dose intravenous penicillin or ampicillin is administered. This inflammation-dependent penetration means that CSF drug concentrations fall as meningitis resolves, which underscores the importance of maintaining full doses throughout the course of therapy.
Option A: Option A is incorrect: increased cerebral blood flow does not by itself increase CSF drug concentration; the barrier functions as the primary determinant, not total drug delivery; increased flow delivers more drug to the barrier but does not change barrier permeability.
Option B: Option B is incorrect: inflammatory cytokines do not upregulate OAT1 in a way that meaningfully reduces penicillin renal clearance; the mechanism of improved CSF penetration is local at the blood-brain barrier, not systemic plasma level elevation.
Option C: Option C is incorrect: while LPS does contribute to inflammatory activation of brain endothelium, it does not directly inhibit P-glycoprotein by trapping drug within the CNS; the mechanism involves altered tight junction integrity and transporter regulation, not substrate-level inhibition by LPS itself.
Option E: Option E is incorrect: penicillins are hydrophilic, ionized molecules whose penetration of lipid membranes is inherently poor regardless of temperature; their improved CNS entry during inflammation does not involve lipophilicity changes or transcellular lipid partitioning.
9. A 29-year-old man is diagnosed with secondary syphilis. He has no history of penicillin allergy. Which of the following statements about penicillin therapy for syphilis is correct?
A) Amoxicillin is preferred over penicillin G for secondary syphilis because its superior oral bioavailability (80–90%) achieves treponemicidal plasma concentrations without the need for injection
B) Doxycycline is equally efficacious to penicillin G for all stages of syphilis, including neurosyphilis, and should be used as first-line therapy in patients who prefer oral treatment
C) Penicillin G remains the drug of choice for all stages of syphilis because Treponema pallidum has never developed acquired penicillin resistance, and no alternative achieves equivalent efficacy for neurosyphilis or congenital syphilis
D) Piperacillin-tazobactam is preferred over penicillin G for secondary syphilis because its broader spectrum ensures coverage of co-infecting organisms commonly transmitted with T. pallidum
E) Ceftriaxone is preferred over penicillin G for secondary syphilis because its longer half-life allows once-daily intramuscular dosing and its greater beta-lactamase stability provides more reliable treponemicidal activity
ANSWER: C
Rationale:
Treponema pallidum, the causative organism of syphilis, retains universal susceptibility to penicillin G after decades of clinical use. No acquired penicillin resistance has ever been documented in T. pallidum — a unique characteristic among bacterial pathogens. Penicillin G (benzylpenicillin) is the CDC-recommended drug of choice for all stages of syphilis: benzathine penicillin G (a long-acting formulation providing sustained low-level treponemicidal concentrations) for early syphilis, and aqueous penicillin G given intravenously for neurosyphilis and congenital syphilis. No alternative antibiotic has been demonstrated to achieve equivalent outcomes for neurosyphilis or congenital syphilis; even in penicillin-allergic patients, desensitization followed by penicillin therapy is recommended for neurosyphilis and pregnancy-associated syphilis rather than using alternative agents.
Option A: Option A is incorrect: amoxicillin is not an established treatment for syphilis; the specific pharmacokinetic profile of benzathine penicillin G — providing sustained low-level treponemicidal concentrations over 2–3 weeks — is critical for early syphilis, and oral amoxicillin does not replicate this profile; furthermore, T. pallidum cannot be cultured to confirm cure with oral regimens.
Option B: Option B is incorrect: doxycycline is an alternative for early syphilis in non-pregnant penicillin-allergic patients, but it is not equivalent to penicillin G for neurosyphilis (poor CSF penetration) or congenital syphilis (contraindicated in pregnancy and neonates); characterizing it as equally efficacious for all stages is incorrect.
Option D: Option D is incorrect: piperacillin-tazobactam is not indicated for syphilis; the premise of needing broader spectrum for T. pallidum is incorrect since penicillin G provides adequate treponemicidal activity, and co-infection management is handled by separate agents; using pip-tazo for syphilis would be inappropriate and wasteful.
Option E: Option E is incorrect: ceftriaxone is used in some investigational and off-label protocols for syphilis and has treponemicidal activity, but it is not the CDC-recommended drug of choice; penicillin G has the strongest evidence base; additionally, the suggestion that penicillin G needs "greater beta-lactamase stability" is irrelevant since T. pallidum does not produce beta-lactamases.
10. Regarding the epidemiology and molecular characteristics of extended-spectrum beta-lactamases (ESBLs), which of the following statements is correct?
A) ESBL-producing organisms are identified clinically by resistance to carbapenems combined with susceptibility to third-generation cephalosporins, a pattern that distinguishes them from AmpC-producing strains
B) The TEM-1 enzyme is the globally dominant ESBL; it is carried exclusively on chromosomally integrated gene cassettes and cannot be transferred between bacterial species
C) ESBL-producing organisms are reliably treated with piperacillin-tazobactam whenever susceptibility testing reports the organism as susceptible, because the inhibitor tazobactam reliably protects piperacillin from ESBL-mediated hydrolysis in vivo
D) ESBLs are classified as Ambler class B enzymes because they require zinc cofactors to achieve the expanded hydrolytic spectrum that includes third-generation cephalosporins and aztreonam
E) CTX-M-15, a CTX-M family ESBL, is the globally dominant extended-spectrum beta-lactamase; it is carried on mobile genetic elements including plasmids and transposons, facilitating interspecies spread, and confers resistance to most penicillins, cephalosporins, and aztreonam while susceptibility to carbapenems is generally retained
ANSWER: E
Rationale:
CTX-M-15 (CTX-M: cefotaxime-Munich, a designation reflecting the hydrolytic preference for cefotaxime and the laboratory where the enzyme family was first characterized) is the globally dominant extended-spectrum beta-lactamase, having largely displaced the older TEM and SHV ESBL variants over the past two decades. The CTX-M enzymes are class A serine beta-lactamases that hydrolyze third-generation cephalosporins and aztreonam in addition to penicillins. Critically, CTX-M-15 and other CTX-M variants are carried on mobile genetic elements — plasmids, transposons, and integrons — that facilitate horizontal transfer between different Enterobacteriaceae species and even across gram-negative genera, driving rapid worldwide dissemination. ESBL-producing organisms typically retain susceptibility to carbapenems (which are not hydrolyzed efficiently by class A ESBLs) and may show in vitro susceptibility to beta-lactam inhibitor combinations.
Option A: Option A is incorrect: ESBL-producing organisms are resistant to penicillins and most cephalosporins but susceptible to carbapenems — the pattern is the reverse of what is described; resistance to carbapenems while retaining cephalosporin susceptibility would be a very unusual pattern not characteristic of ESBLs.
Option B: Option B is incorrect: CTX-M-15, not TEM-1, is the globally dominant ESBL; furthermore, ESBLs are predominantly plasmid-borne and transfer readily between species — chromosomal exclusivity is the opposite of their epidemiological behavior; TEM-1 is a common penicillinase but not itself an ESBL in its wild-type form.
Option C: Option C is incorrect: the MERINO trial demonstrated that piperacillin-tazobactam should not be used as definitive therapy for ESBL bacteremia even when the organism tests susceptible in vitro, due to the inoculum effect; this option contradicts established trial evidence.
Option D: Option D is incorrect: ESBLs are Ambler class A serine beta-lactamases, not class B; Ambler class B enzymes are the metallo-beta-lactamases (NDM, VIM, IMP) that use zinc cofactors; the ESBL designation specifically refers to class A enzymes that have mutated to extend their hydrolytic reach to oxyimino-cephalosporins.
11. A patient with a urinary tract infection has a urine culture growing Enterobacter cloacae. The susceptibility report shows resistance to ampicillin, all cephalosporins tested, and resistance to amoxicillin-clavulanate, but susceptibility to carbapenems. Which resistance mechanism best explains this pattern?
A) The organism harbors a plasmid-encoded TEM-type ESBL (extended-spectrum beta-lactamase) that hydrolyzes all penicillins and cephalosporins; in vitro resistance to amoxicillin-clavulanate is unexpected and suggests a co-existing porin mutation
B) The organism expresses chromosomally encoded, inducible AmpC cephalosporinase — a class C serine beta-lactamase that hydrolyzes first- through third-generation cephalosporins and is not inhibited by clavulanate, sulbactam, or tazobactam, but does not efficiently hydrolyze carbapenems
C) The organism produces an NDM (New Delhi metallo-beta-lactamase) enzyme that hydrolyzes carbapenems and all cephalosporins; apparent carbapenem susceptibility on standard disk diffusion may underestimate MIC due to inoculum effects
D) The organism has upregulated MexAB-OprM efflux pump expression, which exports both cephalosporins and beta-lactam inhibitors from the periplasm before they can inhibit PBPs or beta-lactamases
E) The organism has acquired a plasmid-encoded KPC (Klebsiella pneumoniae carbapenemase) that hydrolyzes all beta-lactams including carbapenems; reported susceptibility to carbapenems reflects inadequate testing sensitivity rather than true susceptibility
ANSWER: B
Rationale:
Enterobacter cloacae and other ESKAPE organisms including Serratia marcescens, Citrobacter freundii, Morganella morganii, and Providencia species (the ESCAPPM group) harbor chromosomally encoded AmpC beta-lactamases that are inducible by beta-lactam exposure. AmpC enzymes are Ambler class C serine beta-lactamases with a hydrolytic spectrum that includes first-, second-, and third-generation cephalosporins and cephamycins. A critical feature distinguishing AmpC from class A ESBLs is that AmpC enzymes are not inhibited by clavulanate, sulbactam, or tazobactam; this explains the observed resistance to amoxicillin-clavulanate (the inhibitor cannot suppress AmpC activity). Carbapenems are poor substrates for AmpC hydrolysis, explaining retained susceptibility. Clinically, third-generation cephalosporins should be avoided even for apparently susceptible Enterobacter because AmpC induction or derepression during therapy can select for stable AmpC-overproducing mutants with high-level cephalosporin resistance, a phenomenon called on-therapy resistance emergence.
Option A: Option A is incorrect: TEM-type ESBLs are class A serine enzymes that are inhibited by clavulanate in vitro; resistance to amoxicillin-clavulanate is not expected for a typical ESBL (unless co-existing mechanisms are present); the pattern of clavulanate-stable resistance in Enterobacter specifically points to AmpC, not TEM ESBL.
Option C: Option C is incorrect: NDM is a metallo-beta-lactamase that efficiently hydrolyzes carbapenems; genuine NDM-producing organisms are not susceptible to carbapenems; a carbapenem-susceptible pattern argues against NDM.
Option D: Option D is incorrect: MexAB-OprM is a Pseudomonas aeruginosa-specific efflux pump system; Enterobacter cloacae does not express this pump, and efflux pump upregulation alone does not produce the specific pattern of clavulanate-stable cephalosporin resistance observed here.
Option E: Option E is incorrect: KPC produces carbapenem resistance; a carbapenem-susceptible organism does not harbor KPC; attributing reported carbapenem susceptibility to testing insensitivity contradicts established microbiology laboratory performance for carbapenem MIC determination.
12. A 52-year-old woman with MSSA (methicillin-susceptible Staphylococcus aureus) bacteremia is currently receiving vancomycin empirically while awaiting susceptibility results. Susceptibility now confirms MSSA. What is the most appropriate next step in antibiotic management?
A) Continue vancomycin because it covers MSSA adequately and avoids the risk of hypersensitivity reactions associated with penicillinase-stable penicillins in bacteremic patients
B) Switch to daptomycin because it achieves superior bactericidal activity against MSSA compared to both vancomycin and antistaphylococcal penicillins, with a lower risk of nephrotoxicity
C) Switch to cefazolin because it is a first-generation cephalosporin with activity against MSSA and is equivalent to antistaphylococcal penicillins for all serious MSSA infections including endocarditis
D) Switch to nafcillin or oxacillin (antistaphylococcal penicillins) because clinical outcome studies demonstrate superior efficacy compared to vancomycin for MSSA bacteremia, with lower treatment failure and mortality rates
E) Add rifampin to vancomycin to achieve combination bactericidal activity against MSSA that approximates the efficacy of antistaphylococcal penicillins as monotherapy
ANSWER: D
Rationale:
For confirmed MSSA bacteremia, antistaphylococcal penicillins — nafcillin or oxacillin parenterally — are the drugs of choice and are clearly superior to vancomycin in clinical outcome studies. Multiple observational and comparative studies have demonstrated that patients with MSSA bacteremia treated with antistaphylococcal penicillins experience significantly lower treatment failure rates, lower 30-day mortality, and faster microbiological clearance compared to those treated with vancomycin. The mechanistic basis for vancomycin's inferiority against MSSA is multifactorial: vancomycin's intrinsically slower bactericidal kinetics against staphylococci, its higher minimum bactericidal concentration (MBC) relative to MIC for MSSA, and limited tissue penetration compared to beta-lactams all contribute. Definitive therapy for MSSA bacteremia should therefore always include de-escalation to an antistaphylococcal penicillin whenever susceptibility is confirmed and there is no contraindication.
Option A: Option A is incorrect: vancomycin is clearly inferior to antistaphylococcal penicillins for MSSA; continuing vancomycin when susceptibility to nafcillin or oxacillin is confirmed represents a clinically consequential substandard practice; the concern about hypersensitivity does not justify inferior outcomes without a specific penicillin allergy history.
Option B: Option B is incorrect: daptomycin achieves good outcomes in MSSA bacteremia and right-sided endocarditis, but it is not established as superior to antistaphylococcal penicillins; furthermore, daptomycin is inactivated in pulmonary surfactant and cannot be used for pneumonia; antistaphylococcal penicillins remain the standard of care where tolerated.
Option C: Option C is incorrect: cefazolin is a reasonable alternative to antistaphylococcal penicillins for some MSSA infections and is used when penicillin allergy is a concern, but there is emerging evidence suggesting it may be less effective than nafcillin for high-inoculum infections such as endocarditis due to the inoculum effect with cefazolin's susceptibility to type A penicillinases; antistaphylococcal penicillins remain preferred for endocarditis.
Option E: Option E is incorrect: adding rifampin to vancomycin does not achieve equivalent outcomes to antistaphylococcal penicillin monotherapy; rifampin resistance emerges rapidly when it is used as monotherapy or in combinations with inadequate bactericidal activity; this approach does not address the fundamental inferiority of vancomycin for MSSA.
13. The short half-lives of most penicillins (penicillin G approximately 0.5 hours, ampicillin approximately 1–2 hours) are primarily due to active tubular secretion in the proximal tubule. Which transporter mediates this secretion, and what was the historical pharmacological strategy used to prolong penicillin half-life?
A) OAT1 (organic anion transporter 1) in the proximal tubule mediates active tubular secretion of penicillins; probenecid was used as a competitive inhibitor of OAT1 to reduce penicillin elimination and extend its half-life, increasing plasma concentrations and reducing dosing frequency
B) P-glycoprotein (P-gp) in the proximal tubule apical membrane secretes penicillins into the tubular lumen; verapamil was used as a P-gp inhibitor to reduce renal elimination and prolong drug exposure
C) OCT2 (organic cation transporter 2) in the proximal tubule mediates penicillin secretion; cimetidine was used as a competitive OCT2 inhibitor to reduce tubular secretion of penicillin G in patients with normal renal function
D) MRP2 (multidrug resistance-associated protein 2) on the apical proximal tubule membrane mediates active secretion of penicillins; sulfinpyrazone was used to competitively inhibit MRP2 and reduce renal penicillin clearance
E) MATE1 (multidrug and toxin extrusion protein 1) transporter in the proximal tubule mediates penicillin secretion; pyrimethamine was historically used as a MATE1 inhibitor to extend the half-life of penicillin G for once-daily dosing
ANSWER: A
Rationale:
Most penicillins are eliminated predominantly by the kidney through a combination of glomerular filtration and active tubular secretion. The active secretion component is mediated by OAT1 (organic anion transporter 1) located on the basolateral membrane of proximal tubule cells, which actively transports organic anions — including penicillins — from the peritubular blood into the tubular epithelial cell for subsequent secretion into the tubular lumen. This active transport is the primary reason for the short half-lives of penicillins: they are cleared from the plasma far faster than glomerular filtration alone would predict. Probenecid is a uricosuric agent that competitively inhibits OAT1, reducing penicillin tubular secretion and thereby extending its plasma half-life and increasing plasma concentrations. In the early antibiotic era when penicillin was scarce and expensive, probenecid was co-administered to reduce penicillin dosing requirements. Today, probenecid is occasionally used to achieve high plasma concentrations of penicillin G for specific indications (such as some protocols for Lyme disease or gonorrhea) or to reduce dosing frequency of certain agents.
Option B: Option B is incorrect: P-glycoprotein is an ATP-binding cassette transporter that handles large lipophilic molecules and is not the primary transporter for the small hydrophilic penicillin molecules; verapamil is a P-gp inhibitor used in oncology research contexts, not for penicillin pharmacokinetic manipulation.
Option C: Option C is incorrect: OCT2 (organic cation transporter 2) handles positively charged organic cations such as metformin and creatinine; penicillins are organic anions and are not substrates for OCT2; cimetidine inhibits OCT2 to reduce creatinine secretion but has no relevant effect on penicillin elimination.
Option D: Option D is incorrect: MRP2 is an apical efflux transporter involved in biliary and tubular secretion of certain conjugated organic anions and drugs, but it is not the primary mediator of penicillin tubular secretion, and sulfinpyrazone-MRP2 inhibition is not an established strategy for penicillin pharmacokinetic modification.
Option E: Option E is incorrect: MATE transporters are involved in the secretion of organic cations and some amphoteric compounds; penicillins are not MATE substrates, and pyrimethamine is used clinically as a DHFR inhibitor for antimalarial and anti-toxoplasma therapy, not as a penicillin secretion inhibitor.
14. A Pseudomonas aeruginosa isolate from a ventilator-associated pneumonia is reported as resistant to meropenem and imipenem but susceptible to piperacillin-tazobactam, ceftazidime, and aztreonam. Which resistance mechanism most specifically explains selective carbapenem resistance with preserved susceptibility to other beta-lactams?
A) Upregulation of the MexAB-OprM efflux pump system, which has high affinity for carbapenems but poor affinity for piperacillin and aztreonam, producing a selective carbapenem-resistant phenotype
B) Acquisition of a plasmid encoding a KPC (Klebsiella pneumoniae carbapenemase) class A serine carbapenemase that preferentially hydrolyzes carbapenems while leaving extended-spectrum penicillins and aztreonam largely intact
C) Loss or mutation of the OprD porin channel, which serves as the primary route of carbapenem entry into Pseudomonas aeruginosa; because other beta-lactams use alternative OmpF/OmpC-type porins for entry, OprD loss produces selective carbapenem resistance while other beta-lactam activity is preserved
D) Acquisition of a chromosomal mutation in the carbapenem-binding site of PBP3, which reduces meropenem and imipenem affinity without affecting the PBP1 and PBP2 targets of piperacillin and ceftazidime
E) Overexpression of the inducible chromosomal AmpC beta-lactamase, which in Pseudomonas aeruginosa has evolved a mutant active site that preferentially hydrolyzes the imipenem and meropenem beta-lactam ring while leaving the piperazinyl side chain of piperacillin sterically protected
ANSWER: C
Rationale:
In Pseudomonas aeruginosa, carbapenems (meropenem, imipenem) enter the bacterial periplasm primarily through a specific porin channel called OprD, which is a substrate-specific channel with high affinity for basic amino acids and, importantly, carbapenems. Carbapenems are too large or have structural features that prevent efficient passage through the general porins used by other beta-lactams in gram-negative organisms. Loss or downregulation of OprD — through mutation, transcriptional repression, or insertion sequence disruption — therefore produces selective resistance to carbapenems (meropenem and imipenem) while leaving other beta-lactams largely unaffected, because piperacillin, ceftazidime, and aztreonam gain periplasmic access through separate OprF and other porin channels. This is one of the most clinically important and common mechanisms of non-carbapenemase-mediated carbapenem resistance in Pseudomonas.
Option A: Option A is incorrect: MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas do export carbapenems to some degree, but MexAB-OprM upregulation produces broad-spectrum resistance affecting multiple drug classes including piperacillin and fluoroquinolones, not selective carbapenem resistance with preserved piperacillin and aztreonam susceptibility; the selective pattern described points to OprD loss.
Option B: Option B is incorrect: KPC produces resistance to all carbapenems and most other beta-lactams including piperacillin-tazobactam and cephalosporins; an isolate with KPC would not typically test susceptible to piperacillin-tazobactam and ceftazidime; additionally, KPC is far less common in Pseudomonas than in Klebsiella.
Option D: Option D is incorrect: while PBP mutations do contribute to resistance in some contexts, the highly selective pattern of carbapenem resistance with preserved susceptibility to all other tested beta-lactams is most specifically explained by OprD loss; PBP3 mutations would typically affect multiple beta-lactams that share that target.
Option E: Option E is incorrect: chromosomal AmpC in Pseudomonas aeruginosa does not have a mutant active site that selectively hydrolyzes carbapenems; wild-type and inducible AmpC enzymes are poor carbapenem hydrolyzers; the premise of an evolved AmpC carbapenemase in Pseudomonas describes a different phenomenon (specifically, class C carbapenemases are rare) and does not explain the clinical pattern observed.
15. A patient with streptococcal pharyngitis confirmed on culture requires antibiotic treatment. The clinician considers both penicillin G and penicillin V. Which of the following correctly describes the pharmacological basis for selecting between these two natural penicillins?
A) Penicillin G is preferred for oral outpatient therapy because its benzyl side chain increases gastric acid stability, achieving higher peak plasma concentrations than penicillin V at equivalent doses
B) The two agents are interchangeable for all indications because they share identical spectra of activity, identical pharmacokinetics after oral administration, and equivalent rates of adverse effects
C) Penicillin V is preferred when intravenous therapy is required because its phenoxymethyl side chain improves aqueous solubility, enabling higher-concentration intravenous formulations than are possible with penicillin G
D) Penicillin G is preferred for oral therapy in pediatric patients because it is formulated as a palatable suspension, while penicillin V is available only as tablets unsuitable for children unable to swallow solid dosage forms
E) Penicillin V is the preferred oral agent because the phenoxymethyl side chain confers acid stability, yielding oral bioavailability of approximately 60–73%, whereas penicillin G is acid-labile, undergoes degradation in gastric acid, and is available only for parenteral administration
ANSWER: E
Rationale:
The critical pharmacological difference between penicillin G (benzylpenicillin) and penicillin V (phenoxymethylpenicillin) lies in their acid stability. Penicillin G contains a benzyl side chain that is susceptible to hydrolysis by gastric acid, resulting in variable and unreliable absorption after oral administration; it is therefore formulated only for parenteral use (intramuscular or intravenous). Penicillin V was developed specifically to address this limitation: the benzyl group is replaced by a phenoxymethyl group, which provides steric protection of the adjacent amide bond against acid-catalyzed hydrolysis. The result is an acid-stable penicillin with oral bioavailability of approximately 60–73%, adequate for outpatient use. Both agents share essentially identical antibacterial spectra — excellent activity against streptococci, Treponema pallidum, oral anaerobes, and Neisseria meningitidis. For streptococcal pharyngitis requiring oral therapy, penicillin V is appropriate and cost-effective.
Option A: Option A is incorrect: penicillin G is not acid-stable and is not available as an oral preparation; the benzyl side chain does not provide gastric acid protection — it is precisely the lack of such protection that necessitates parenteral formulation.
Option B: Option B is incorrect: the two agents do not have identical pharmacokinetics after oral administration; penicillin G is not reliably absorbed orally due to acid lability, while penicillin V is well absorbed; they are not interchangeable for oral routes.
Option C: Option C is incorrect: penicillin V is the oral agent, not the intravenous one; penicillin G (specifically aqueous penicillin G sodium or potassium salt) is the parenteral natural penicillin used intravenously for serious infections.
Option D: Option D is incorrect: penicillin V is available in both tablet and liquid suspension formulations suitable for children; penicillin G does not have a standard palatable oral formulation; this option has the pharmacological properties of the two agents reversed.
16. PBP2a (penicillin-binding protein 2a), encoded by the mecA gene in MRSA (methicillin-resistant Staphylococcus aureus), differs structurally from native staphylococcal PBPs in a way that confers beta-lactam resistance. Which statement best describes the functional consequence of this structural difference?
A) PBP2a contains a modified active site in which the catalytic serine residue is replaced by a threonine, creating a steric clash with the beta-lactam carbonyl that prevents acyl-enzyme intermediate formation at any drug concentration
B) PBP2a has a structurally altered active site that dramatically reduces its affinity for all beta-lactam antibiotics, such that clinical drug concentrations cannot achieve sufficient acylation to abolish transpeptidase activity; PBP2a continues to cross-link peptidoglycan and support cell growth even in the presence of beta-lactams
C) PBP2a lacks the active-site serine residue entirely due to a frameshift mutation in mecA, making it chemically incapable of forming an acyl-enzyme intermediate with any substrate including its natural D-alanyl-D-alanine substrate; resistance is achieved by having other PBPs compensate
D) PBP2a has a closed active site conformation that physically excludes beta-lactam molecules based on size, while the natural peptidoglycan substrate gains access through an allosteric opening mechanism triggered by binding at a remote sensor domain
E) PBP2a is constitutively expressed at extremely high copy numbers in MRSA, saturating all available beta-lactam molecules before they can reach the lower-copy-number native PBPs that are essential for cell wall synthesis
ANSWER: B
Rationale:
PBP2a is a modified transpeptidase with a functional active-site serine residue — meaning it retains enzymatic activity — but the surrounding active site architecture has undergone structural changes that dramatically reduce its affinity for beta-lactam antibiotics. In native PBPs, the beta-lactam ring mimics the D-alanyl-D-alanine transition state of the natural substrate, allowing the beta-lactam carbonyl to efficiently acylate the catalytic serine. In PBP2a, allosteric conformational changes and alterations in the active site geometry mean that much higher beta-lactam concentrations would be required to achieve the same degree of acylation — concentrations that far exceed what can be achieved clinically with any approved beta-lactam except ceftaroline. Because PBP2a retains full transpeptidase activity with its natural peptidoglycan substrate, MRSA can continue synthesizing and cross-linking cell wall peptidoglycan even in the presence of beta-lactam concentrations that completely inactivate all native PBPs. The crystal structure of PBP2a has confirmed the low affinity basis and, importantly, revealed an allosteric activation mechanism where cell wall fragments open the active site to allow natural substrate access.
Option A: Option A is incorrect: PBP2a retains a catalytic serine residue; its resistance mechanism is based on reduced affinity (high Km) for beta-lactams, not on elimination of the serine; if the serine were replaced, PBP2a would lose all transpeptidase activity including against its natural substrate, which would be lethal.
Option C: Option C is incorrect: PBP2a does have a catalytic serine and can form an acyl-enzyme intermediate with its natural D-alanyl-D-alanine substrate; the mechanism is reduced affinity for beta-lactams, not absence of catalytic machinery.
Option D: Option D is incorrect: while there is indeed an allosteric activation mechanism in PBP2a, the resistance is primarily based on reduced affinity for beta-lactams in the active site, not on physical size exclusion; the active site architecture reduces beta-lactam binding affinity rather than physically blocking entry.
Option E: Option E is incorrect: MRSA resistance is not mediated by overproduction of PBP2a to sequester or saturate beta-lactam molecules; the mechanism is intrinsic low affinity of individual PBP2a molecules for beta-lactams, not a pharmacokinetic sink; overproduction alone of a normal-affinity PBP could not confer resistance.
17. A 61-year-old man with Enterococcus faecalis native valve endocarditis requires bactericidal combination therapy. His renal function is normal. Which of the following best explains why penicillin or ampicillin alone is insufficient for endocarditis treatment and what must be added?
A) Enterococcus faecalis produces a constitutive class C AmpC beta-lactamase that hydrolyzes ampicillin; nafcillin is therefore required as the beta-lactamase-stable penicillin, combined with rifampin for biofilm penetration
B) Enterococcus faecalis expresses PBP5, a low-affinity PBP that confers intrinsic ampicillin resistance; high-dose daptomycin must be added to achieve bactericidal activity against PBP5-expressing strains
C) Enterococcus faecalis is inherently resistant to all penicillins via mecA-mediated PBP2a expression; vancomycin combined with gentamicin is the only bactericidal regimen for enterococcal endocarditis
D) Enterococcus faecalis exhibits intrinsic tolerance to beta-lactam bactericidal activity — penicillins and ampicillin are bacteriostatic against enterococci because their cell wall synthesis can continue through tolerant mechanisms — and an aminoglycoside (gentamicin or streptomycin) must be added to achieve synergistic bactericidal killing required for endocarditis cure
E) Enterococcus faecalis lacks the autolytic enzymes that normally complete cell lysis after PBP inhibition; adding a cell membrane-active agent such as daptomycin provides the lytic trigger necessary for bactericidal activity in combination with ampicillin
ANSWER: D
Rationale:
Enterococcus faecalis is intrinsically tolerant to the bactericidal activity of cell wall-active antibiotics, including penicillins, ampicillin, and vancomycin. Tolerance means that while these agents inhibit bacterial growth (bacteriostatic effect), they do not kill the organism reliably; the minimum bactericidal concentration (MBC) far exceeds the minimum inhibitory concentration (MIC), in contrast to the pattern seen with streptococci where the MBC is close to the MIC. The mechanistic basis of enterococcal tolerance includes an unusual ability to survive with incomplete cell wall synthesis and reduced dependence on autolysin-mediated lysis compared to streptococci and staphylococci. Because endocarditis cure requires bactericidal activity (vegetations are large, poorly penetrated bacterial masses in which bacteriostatic drug concentrations may not maintain suppression throughout therapy), this tolerance renders beta-lactam or vancomycin monotherapy inadequate. Combination with an aminoglycoside — gentamicin for most E. faecalis strains, or streptomycin for gentamicin-resistant strains — achieves synergistic bactericidal killing by exploiting the enhanced aminoglycoside uptake that occurs when the cell wall is partially damaged by beta-lactam exposure; the combination kills organisms that neither drug kills alone. High-level aminoglycoside resistance (HLAR), defined by a gentamicin MIC above 500 mcg/mL or streptomycin MIC above 2000 mcg/mL, abolishes this synergy and requires different management.
Option A: Option A is incorrect: Enterococcus faecalis does not produce chromosomal AmpC beta-lactamase; it is intrinsically susceptible to ampicillin; nafcillin has poor enterococcal activity and is not used for enterococcal infections; rifampin is not a standard component of enterococcal endocarditis regimens.
Option B: Option B is incorrect: Enterococcus faecalis does express PBP5, but PBP5 confers intrinsic ampicillin tolerance/resistance in Enterococcus faecium (not E. faecalis); E. faecalis remains susceptible to ampicillin; high-dose daptomycin is used for enterococcal endocarditis only in specific situations and is not the solution to PBP5 resistance in E. faecalis.
Option C: Option C is incorrect: Enterococcus faecalis does not harbor mecA; PBP2a-mediated resistance is a staphylococcal mechanism; enterococcal penicillin susceptibility is intrinsic, and vancomycin-gentamicin is used only when there is penicillin allergy or ampicillin resistance.
Option E: Option E is incorrect: while it is true that enterococcal tolerance involves reduced autolysin activity, daptomycin is not routinely added to ampicillin as a standard bactericidal strategy for E. faecalis endocarditis; the established synergistic combination is a beta-lactam plus aminoglycoside, which has decades of clinical validation and guideline support.
18. KPC (Klebsiella pneumoniae carbapenemase) is a clinically important beta-lactamase conferring carbapenem resistance. Which of the following correctly characterizes the Ambler classification, mechanism of action, and treatment implications of KPC?
A) KPC is an Ambler class A serine beta-lactamase that uses an active-site serine to hydrolyze the beta-lactam ring of carbapenems, penicillins, and most cephalosporins; it is inhibited by avibactam (but not clavulanate or tazobactam), making ceftazidime-avibactam and meropenem-vaborbactam effective treatment options for KPC-producing organisms
B) KPC is an Ambler class B metallo-beta-lactamase that requires zinc cofactors to hydrolyze carbapenems; it can be inhibited by EDTA chelation of zinc in vitro, and avibactam-based combinations restore susceptibility to ceftazidime in KPC-producing organisms
C) KPC is an Ambler class C AmpC-type cephalosporinase that has mutated to gain carbapenemase activity; it is chromosomally encoded and constitutively expressed in all Klebsiella pneumoniae strains, explaining the worldwide prevalence of KPC-producing carbapenem-resistant Enterobacterales
D) KPC is an Ambler class D OXA-type enzyme that hydrolyzes oxacillin and carbapenems through a serine-based mechanism; it is primarily found in Acinetobacter baumannii and is effectively treated with ampicillin-sulbactam combination therapy
E) KPC is not inhibited by any currently approved beta-lactamase inhibitor combination and is exclusively treated with polymyxins or tigecycline; new cephalosporin-avibactam combinations have laboratory activity but no clinical efficacy against KPC-producing organisms
ANSWER: A
Rationale:
KPC (Klebsiella pneumoniae carbapenemase) is an Ambler class A serine beta-lactamase — it uses an active-site serine residue, the same catalytic mechanism as common penicillinases and ESBLs, but has evolved a broader hydrolytic spectrum that includes carbapenems. KPC is carried on mobile plasmids and has disseminated globally among Enterobacteriaceae, particularly Klebsiella pneumoniae. A critical feature distinguishing KPC from class A penicillinases and ESBLs is that KPC is not inhibited by the older serine-based inhibitors clavulanate, sulbactam, or tazobactam, but it is effectively inhibited by the newer non-beta-lactam serine inhibitor avibactam and by vaborbactam (a boronic acid inhibitor). This pharmacological distinction forms the basis of the two primary treatment options for KPC-producing carbapenem-resistant Enterobacteriaceae (CRE): ceftazidime-avibactam (where avibactam suppresses KPC) and meropenem-vaborbactam (where vaborbactam suppresses KPC and restores meropenem activity).
Option B: Option B is incorrect: KPC is a class A serine beta-lactamase, not a class B metallo-beta-lactamase; it does not require zinc cofactors; EDTA chelation inhibits class B metallo-beta-lactamases (NDM, VIM, IMP), not KPC; however, the statement about avibactam is partially correct in the wrong context — avibactam does inhibit KPC but because KPC is a serine, not zinc, enzyme.
Option C: Option C is incorrect: KPC is a class A enzyme, not class C; it is plasmid-encoded and not constitutively present in all Klebsiella strains; its spread reflects acquisition of the KPC-encoding plasmid rather than an intrinsic chromosomal property of the species.
Option D: Option D is incorrect: KPC is not an OXA-type enzyme; class D OXA carbapenemases (OXA-23, OXA-48) are found predominantly in Acinetobacter baumannii and Klebsiella but are mechanistically distinct from KPC; sulbactam has some intrinsic activity against Acinetobacter but is not a first-line treatment for KPC-producing Klebsiella.
Option E: Option E is incorrect: KPC is specifically inhibited by avibactam and vaborbactam; ceftazidime-avibactam has established clinical efficacy against KPC-producing organisms in multiple clinical studies and registry data; characterizing it as having only laboratory activity misrepresents the evidence base.
19. A patient with a mild MSSA (methicillin-susceptible Staphylococcus aureus) skin and soft tissue infection is prescribed oral dicloxacillin 500 mg four times daily. Which counseling instruction regarding administration is most important for ensuring adequate drug bioavailability?
A) The medication should be taken with a full glass of milk or an antacid to reduce gastric irritation, since the isoxazolyl side chain of dicloxacillin is directly irritating to gastric mucosa when taken in acidic pH conditions
B) The medication should be taken with food to slow gastric emptying and enhance intestinal absorption, since dicloxacillin's oral bioavailability improves significantly in the fed state compared to the fasted state
C) The medication should be taken on an empty stomach, at least 30–60 minutes before meals or 2 hours after eating, because food significantly reduces dicloxacillin absorption, decreasing peak plasma concentrations and potentially resulting in subtherapeutic drug levels
D) The medication should be taken with a high-fat meal to enhance lymphatic absorption, since dicloxacillin's lipophilicity allows it to partition into chylomicrons in the fed state, substantially increasing systemic bioavailability
E) Timing relative to food intake does not significantly affect dicloxacillin absorption; the patient should simply take the medication at evenly spaced intervals throughout the day regardless of meal timing to maintain consistent plasma levels
ANSWER: C
Rationale:
Dicloxacillin is an isoxazolyl antistaphylococcal penicillin that is orally bioavailable (approximately 50–76% under optimal conditions) but is significantly affected by food. When taken with food, gastric emptying slows, exposing dicloxacillin to prolonged contact with gastric contents and reducing the rate and extent of intestinal absorption; peak plasma concentrations (Cmax) can decrease by 50% or more in the fed state compared to the fasted state. Because dicloxacillin relies on achieving adequate plasma concentrations to maintain fT>MIC throughout the dosing interval, suboptimal absorption can undermine clinical efficacy. Patients should be counseled to take dicloxacillin at least 30–60 minutes before meals or 2 hours after meals. This food-absorption interaction distinguishes dicloxacillin from amoxicillin, for which food has minimal clinical impact on bioavailability.
Option A: Option A is incorrect: dicloxacillin is acid-stable (a property of all isoxazolyl penicillins, enabling oral absorption), and antacid or milk co-administration is not indicated; the concern with dicloxacillin is not gastric mucosal irritation but rather food-mediated reduction of absorption.
Option B: Option B is incorrect: dicloxacillin absorption is reduced, not enhanced, in the fed state; instructing a patient to take it with food directly contradicts established pharmacokinetic data and prescribing information for this drug.
Option D: Option D is incorrect: dicloxacillin does not undergo clinically significant lymphatic absorption via chylomicron incorporation; its oral absorption is via intestinal epithelial transport, and it is not a highly lipophilic drug in the manner required for chylomicron partitioning; high-fat meal instruction is the opposite of what is recommended.
Option E: Option E is incorrect: food timing does significantly affect dicloxacillin absorption, contrary to this option's assertion; failure to counsel on the food-fasting requirement is a documented source of treatment failure for dicloxacillin-treated MSSA infections.
20. An ESBL (extended-spectrum beta-lactamase)-producing Escherichia coli isolate from a urine culture tests susceptible to piperacillin-tazobactam on standard in vitro susceptibility testing. The same organism is isolated from blood cultures in the same patient. What is the most important reason that piperacillin-tazobactam should not be used as definitive therapy for the bloodstream infection despite in vitro susceptibility?
A) Standard susceptibility testing underestimates the MIC (minimum inhibitory concentration) for ESBL producers because the test inoculum is lower than the bacterial burden in urine; the urinary MIC is therefore higher than reported and resistance is more likely
B) Piperacillin-tazobactam is not renally eliminated and therefore achieves inadequate urinary concentrations in the setting of bacteremia with concurrent urinary tract infection, requiring a carbapenem for dual-compartment coverage
C) ESBL-producing E. coli co-expresses constitutive outer membrane porin mutations that prevent tazobactam from reaching its target beta-lactamase in the periplasmic space, regardless of in vitro susceptibility results
D) Tazobactam is removed by protein binding in the bloodstream, leaving free tazobactam concentrations insufficient to inhibit ESBL enzymes; urinary drug concentrations are higher due to tubular secretion and protein unbinding, explaining discordance between urinary susceptibility and bacteremic outcomes
E) The inoculum effect — in bacteremia, the high bacterial burden produces substantially more ESBL enzyme than the standard in vitro test inoculum can generate, overwhelming the inhibitory capacity of tazobactam and allowing uninhibited hydrolysis of piperacillin despite apparent in vitro susceptibility
ANSWER: E
Rationale:
The MERINO trial finding — that piperacillin-tazobactam is inferior to meropenem for ESBL bacteremia despite in vitro susceptibility — is best explained by the inoculum effect. Standard in vitro susceptibility testing uses a fixed bacterial inoculum of approximately 5 × 10⁵ CFU/mL, which produces a defined amount of ESBL enzyme. At this inoculum, tazobactam can effectively inhibit the ESBL and protect piperacillin, yielding a susceptible result. However, in bacteremia, the bacterial burden in bloodstream infections and tissues may substantially exceed the test inoculum, resulting in ESBL enzyme production that overwhelms tazobactam's inhibitory capacity. When tazobactam is saturated, free active ESBL enzyme is available to hydrolyze piperacillin, producing clinical failure despite reported susceptibility. Carbapenems are not susceptible to ESBL hydrolysis and therefore remain effective regardless of inoculum burden. This inoculum effect is the mechanistic explanation for why in vitro ESBL susceptibility to pip-tazo does not predict clinical efficacy in bacteremia.
Option A: Option A is incorrect: standard susceptibility testing reflects urinary isolate characteristics; the concern with ESBL bacteremia is not about testing accuracy for urinary strains but about the inoculum effect in the bloodstream infection itself; the direction of inoculum effect is also reversed in this option — higher inoculum in bacteremia, not in urine, is the clinical concern.
Option B: Option B is incorrect: piperacillin-tazobactam is renally eliminated (greater than 68% of dose), achieves high urinary concentrations, and has no issue with inadequate bacteremic distribution; urinary tract infection and bloodstream infection coverage with pip-tazo is not limited by pharmacokinetic compartmentalization in this way.
Option C: Option C is incorrect: constitutive porin mutations affecting tazobactam periplasmic access are not a well-established mechanism specific to ESBL producers; porin mutations do contribute to resistance in some strains but this is not the primary explanation for the MERINO trial results or the discordance between urinary and bacteremic outcomes.
Option D: Option D is incorrect: while tazobactam does have significant protein binding (approximately 30%), this is accounted for in pharmacokinetic-pharmacodynamic modeling and is not the primary explanation for why pip-tazo fails in ESBL bacteremia; the inoculum effect, not protein binding-mediated inhibitor depletion, is the established mechanistic explanation.
21. A hospitalized patient with acute kidney injury has an eGFR (estimated glomerular filtration rate) of 22 mL/min/1.73 m² and is being treated with piperacillin-tazobactam for a healthcare-associated pneumonia caused by a susceptible organism. Which statement correctly describes the pharmacokinetic consideration and dosing adjustment required?
A) Piperacillin-tazobactam does not require dose adjustment in renal failure because tazobactam undergoes extensive hepatic glucuronidation, compensating for any reduction in piperacillin renal clearance and maintaining the optimal piperacillin-to-tazobactam ratio
B) Both piperacillin and tazobactam are predominantly renally eliminated — piperacillin greater than 68% as unchanged drug, tazobactam similarly renal — and dose reduction or interval extension is required when eGFR falls below approximately 40 mL/min to avoid accumulation and toxicity including neurotoxicity at very high concentrations
C) Only the tazobactam component requires dose adjustment in renal failure; piperacillin clearance is unaffected because it undergoes compensatory biliary secretion that maintains normal plasma half-life independent of renal function
D) Piperacillin-tazobactam dose adjustment in renal failure is required only for the extended infusion formulation; standard 30-minute infusion dosing maintains adequate safety margins through non-renal metabolism even at eGFR below 20 mL/min
E) Piperacillin accumulation in renal failure is clinically insignificant because the drug's short half-life of approximately 1 hour means even doubled half-life at eGFR below 20 mL/min produces peak concentrations only modestly above the normal range, requiring no formal dose adjustment in clinical practice
ANSWER: B
Rationale:
Piperacillin and tazobactam are both predominantly renally eliminated. Piperacillin is cleared predominantly by renal excretion (greater than 68% of a dose recovered as unchanged drug or metabolites in urine) through a combination of glomerular filtration and active tubular secretion via OAT transporters. Tazobactam undergoes limited hepatic metabolism but is likewise predominantly renally excreted. As renal function declines, both components accumulate, and dose adjustment is required when eGFR falls below approximately 40 mL/min. Standard prescribing information and pharmacokinetic guidelines recommend dose reduction or interval extension at this threshold; in severe renal failure (eGFR below 20 mL/min), further dose reduction is required. Accumulation of piperacillin in severe renal failure can cause neurotoxicity including myoclonus and seizures, a toxicity profile similar to that of other renally-cleared beta-lactams at supratherapeutic concentrations. In this patient with eGFR of 22 mL/min, formal dose adjustment is mandatory.
Option A: Option A is incorrect: tazobactam does not undergo extensive hepatic glucuronidation in a way that compensates for renal clearance reduction; both components are renally cleared and both accumulate in renal failure; this option incorrectly implies a hepatic compensation mechanism that does not exist.
Option C: Option C is incorrect: piperacillin does not undergo compensatory biliary secretion that preserves normal clearance in renal failure; it is predominantly renally eliminated and does require dose adjustment; isolating dose adjustment to tazobactam alone is incorrect.
Option D: Option D is incorrect: the route of administration (extended versus standard infusion) does not change the requirement for dose adjustment based on renal function; both infusion strategies require the same renal function-based dose adjustments; non-renal metabolism does not compensate for impaired renal clearance of piperacillin.
Option E: Option E is incorrect: the assumption that modest accumulation is clinically insignificant is incorrect; beta-lactam neurotoxicity is a well-documented consequence of accumulation in renal failure; the half-life of piperacillin approximately doubles or triples in severe renal failure, and without dose reduction, steady-state accumulation can reach clinically toxic levels; formal dose adjustment per prescribing information is required.
22. A 74-year-old man with severe chronic kidney disease (eGFR 12 mL/min/1.73 m²) is admitted for pneumococcal meningitis. He is started on high-dose aqueous penicillin G 4 million units intravenously every 4 hours without dose adjustment. On hospital day 3, he develops myoclonic jerks and a generalized tonic-clonic seizure. Which of the following best explains this adverse event?
A) Penicillin G displaces GABA (gamma-aminobutyric acid) from its binding site on albumin, increasing free GABA concentrations in the CSF (cerebrospinal fluid), paradoxically causing neuronal hyperexcitability through GABA-B receptor overstimulation
B) Penicillin G accumulation causes cholinergic crisis by inhibiting acetylcholinesterase at the neuromuscular junction, producing the clinical picture of fasciculations and seizures identical to organophosphate poisoning
C) At standard doses, penicillin G freely crosses the intact blood-brain barrier; in this patient, very high CSF concentrations have directly damaged the myelin sheath of cortical neurons, producing a demyelinating encephalopathy that manifests as myoclonus and seizures
D) Penicillin G is predominantly renally eliminated and accumulates to very high plasma concentrations in severe renal failure without dose adjustment; high penicillin concentrations act as competitive antagonists at GABA-A receptors in the CNS (central nervous system), producing neuronal hyperexcitability, myoclonus, and seizures
E) Penicillin G crosses the blood-brain barrier preferentially in elderly patients due to age-related reduction in P-glycoprotein efflux expression; accumulation in the CSF activates NMDA (N-methyl-D-aspartate) glutamate receptors, producing excitotoxic seizures
ANSWER: D
Rationale:
Penicillin G is eliminated predominantly by renal excretion (approximately 60–90% as unchanged drug) and has a half-life of approximately 0.5 hours in patients with normal renal function. In severe renal failure, renal clearance is markedly reduced, and without dose adjustment, both the half-life and steady-state plasma concentration rise dramatically with repeated dosing. When plasma penicillin concentrations reach supratherapeutic levels, the drug crosses into the CNS (even without meningeal inflammation, and particularly when high-dose therapy is used for meningitis where barrier permeability is already increased) and reaches concentrations sufficient to exert pharmacological effects at neuronal receptors. The mechanism of penicillin neurotoxicity is competitive antagonism at the GABA-A (gamma-aminobutyric acid type A) chloride channel receptor complex: penicillin inhibits GABA-mediated chloride conductance, reducing inhibitory tone in the CNS, resulting in neuronal hyperexcitability that manifests as myoclonus, asterixis, and generalized tonic-clonic seizures. This adverse effect is well recognized and preventable through appropriate dose reduction in renal failure — for an eGFR of 12 mL/min, the standard 4 million unit dose every 4 hours should be reduced substantially in frequency or dose.
Option A: Option A is incorrect: penicillin G does not displace GABA from albumin binding in a pharmacologically meaningful way; GABA-B receptor overstimulation produces inhibitory, not excitatory, neurological effects and would not cause seizures; the mechanism of penicillin neurotoxicity is GABA-A antagonism, not GABA-B agonism.
Option B: Option B is incorrect: penicillin G does not inhibit acetylcholinesterase and does not produce a cholinergic toxidrome; organophosphate poisoning is characterized by muscarinic excess (SLUDGE: salivation, lacrimation, urination, defecation, GI cramping, emesis), not the myoclonus and seizure pattern seen with penicillin neurotoxicity.
Option C: Option C is incorrect: penicillin G does not cross the intact blood-brain barrier freely at standard doses (CSF-to-plasma ratio approximately 1–2% with normal meninges), and its neurotoxicity is not mediated by demyelination; demyelinating encephalopathy is a distinct neuropathological process unrelated to GABA-A receptor antagonism; the toxicity is pharmacodynamic, not structural.
Option E: Option E is incorrect: while age-related changes in P-glycoprotein expression are observed, this is not the primary mechanism driving penicillin neurotoxicity in this clinical scenario; NMDA receptor activation causing excitotoxicity describes the mechanism of some other neurotoxins (such as domoic acid) but not penicillin; the GABA-A antagonism mechanism is well established for beta-lactam neurotoxicity.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.